A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)

Chandra, J., Woo, W. P., Finlayson, N., Liu, H. Y., McGrath, M., Ladwa, R., Brauer, M., Xu, Y., Hanson, S., Panizza, B., Frazer, I. H. and Porceddu, S. V.  A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC).  Cancer Immunology, Immunotherapy (2020).  doi: 10.1007/s00262-020-02720-7

Privacy Preference Center

Necessary

Advertising

Analytics

Other